A 56-year-old man presented to a peripheral hospital in New Zealand with severe Plasmodium falciparum malaria with cerebral involvement and subsequently developed multi-system organ failure. Activated protein C was used in an attempt to stop the cascade of events into multiorgan failure.
Severe infection with P. falciparum is life-threatening and appears to activate a hypercoagulable state similar to that of severe sepsis. Activated protein C is currently used in the treatment of severe sepsis and may provide a new adjuvant therapy for severe P. falciparum malaria.
GraceD., LaveryG.G., JacksonP., CanavanD.A., FeeJ.P.H.Intensive care management of multiorgan dysfunction due to falciparum malaria in a married couple.Anaesthesia1994; 49: 686–690.
2.
LosertH., SchmidK., WilfingA., WinklerS., StaudingerT., KletzmayrJ.Experiences with severe P. falciparum malaria in the intensive care unit.Intensive Care Med2000; 26: 195–201.
3.
GregorakosL., SakayanniK., HroniD., HarizopoulouV., GeorgiadouF., AdamidouM.Management of severe and complicated malaria in the intensive care unit.Intensive Care Med1999; 25: 744–747.
4.
WhiteN.J.Not much progress in treatment of cerebral malaria.Lancet1998; 352: 594–595.
5.
NjugunaP.W., NewtonCRJCManagement of severe falciparum malaria.J Postgrad Med2004; 50: 45–50.
6.
DavisT.M., SupanaranondW., PukrittayakameeS., KarbwangJ., MoluntoP., MekthonS.A safe and effective-infusion regimen for rapid quinine loading in severe falciparum malaria.J Infect Dis1990; 161: 1305–1308.
7.
LiangJ., StreatS., TorranceJ., SleighJ., FreebairnR., RamsayM.Drotrecogin alfa (recombinant human activated protein C) in severe sepsis—a New Zealand viewpoint.N Z Med J2003; 116: U586.
BruneelF., HocquelouxL., AlbertiC., WolffM., ChevretS., BedosJ.P.The clinical spectrum of severe imported falciparum malaria in the intensive care unit; report of 188 cases in adults.Am J Respir Crit Care Med2003; 167: 684–689.
10.
Notifiable and Other diseases in New Zealand—2005 surveillance report. Available online from: http://www.surv.esr.cri.nz Accessed January 2006.
11.
BoneR.C., BalkR.A., CerraF.B., DellingerR.P., FeinA.M., KnausW.A.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.Chest1992; 101: 1644–1655.
12.
HemmerC.J., KernP., HolstF.G.E., RadtkeK.P., EgbringR., BierhausA.Activation of the host response in human—Plasmodium falciparum malaria: Relation of parasitaemia to tumor necrosis factor/cachectin, thrombin-anti-thrombin III, protein C levels.Am J Med1991; 91: 37–44.
VogetsederA., OspeltC., ReindlM., SchoberM., SchmutzhardE.Time course of coagulation parameters, cytokines and adhesion molecules in Plasmodium falciparum malaria.Trop Med Int Health2004; 9: 767–773.
15.
DettenmeierP., SwindellB., StroudM., ArkinsN., HowardA.Role of activated protein C in the pathophysiology of severe sepsis.Am J Crit Care2003; 12: 518–524.
16.
ClarkI.A., CowdenW.B.The pathophysiology of falciparum malaria.Pharmacol Ther2003; 99: 221–260.
17.
FourrierF.Recombinant human activated protein C in the treatment of severe sepsis: An evidence-based review.Crit Care Med2004; 32(11 Suppl): S534–S541.
18.
MohantyD., GhoshK., NandwaniS.K., ShettyS., PhillipsC., RizviS.Finbrinolysis, inhibitors of coagulation, and monocyte derived coagulant activity in acute malaria.Am J Hematol1997; 54: 23–29.
19.
RaggioM.J., MorrisP.E.Drotrecogin Alfa.Drugs of Today2004; 40: 517–538.
20.
McCoyC., MatthewsS.J.Drotrecogin Alfa (recombinant human activated protein C) for the treatment of severe sepsis.Clin Ther2003; 25: 396–421.
21.
HaleyM., CuiX., MinneciP.C., DeansK.J., NatansonC., EichackerP.Q.Recombinant human activated protein C in sepsis: Assessing its clinical use.Am J Med Sci2004; 328: 215–219.
KohK.H., ChewP.H., KiyuA.A retrospective study of malarial infections in an intensive care unit of a general hospital in Malaysia.Singapore Med J2004; 45: 28–36.
